Viritis Ltd

Viritis is a biotech company pioneering a next-generation antisense-based platform for rapid development of antiviral drugs. Our novel technology targets all strains of a given virus, offering a scalable and precise solution for current and emerging viral threats. Our platform combines AI-driven algorithms with patented molecule design to bind specifically to viral RNA. Once attached, it activates the cell’s innate defense mechanisms, degrading the virus from within— without harming the host. After completing its function, the molecule naturally disintegrates within hours, leaving no harmful residues. In POC studies, our platform demonstrated 97.1% cellular protection against the target virus. Its innovative structure also makes it highly stable, can be lyophilize, and easy to store and transport—ideal for global deployment.